{"public_id":"cl_24fc5202895056c91d40bada3755a04c","status":"active","superseded_by_public_id":null,"corpus_id":220930733,"text":"gH/gL complexes might be the major target inducing neutralizing activity against HCMV.","confidence":0.92,"paper":{"corpus_id":220930733,"title":"Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes","url":"https://sah.borca.ai/papers/220930733"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.92,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_145bcf4dbe631ebd9c72e30bd5bf3463","name":"gH/gL complexes","description":"HCMV glycoprotein complexes containing gH and gL, including the gH/gL/gO and gH/gL/UL128-131A forms.","types":["glycoprotein complex"],"url":"https://sah.borca.ai/concepts/co_145bcf4dbe631ebd9c72e30bd5bf3463"},{"public_id":"co_969a14c38f62d8f93e32427277e2f19f","name":"neutralizing activity against HCMV","description":"The capacity of antibodies to block HCMV infection.","types":["biological activity"],"url":"https://sah.borca.ai/concepts/co_969a14c38f62d8f93e32427277e2f19f"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_24fc5202895056c91d40bada3755a04c"}